EC
EcoR1 Capital Portfolio holdings
AUM
$1.69B
This Quarter Return
-12.57%
1 Year Return
+7.54%
3 Year Return
+113.08%
5 Year Return
+306.58%
10 Year Return
+4,328.75%
AUM
$3.2B
AUM Growth
+$3.2B
(+2%)
Cap. Flow
+$674M
Cap. Flow
% of AUM
21.1%
Top 10 Holdings %
Top 10 Hldgs %
58.79%
Holding
97
New
22
Increased
20
Reduced
15
Closed
11
Top Buys
| 1 |
Sarepta Therapeutics
SRPT
|
$162M |
| 2 |
Zai Lab
ZLAB
|
$97.8M |
| 3 |
Arvinas
ARVN
|
$92.4M |
| 4 |
Acadia Pharmaceuticals
ACAD
|
$71M |
| 5 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$64.7M |
Top Sells
| 1 |
CRISPR Therapeutics
CRSP
|
$81.7M |
| 2 |
GRTS
Gritstone bio, Inc. Common Stock
GRTS
|
$77.3M |
| 3 |
Arcus Biosciences
RCUS
|
$71.3M |
| 4 |
Protagonist Therapeutics
PTGX
|
$53.5M |
| 5 |
SAGE
Sage Therapeutics
SAGE
|
$40M |
Sector Composition
| 1 | Healthcare | 99.16% |
| 2 | Financials | 0.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Prothena Corp
PRTA
$441M
| $424M | 13.25% | 11,584,280 +300,000 | +3% | +$11M |
|
2
Apellis Pharmaceuticals
APLS
$3.48B
| $263M | 8.24% | 5,183,431 +1,149,549 | +28% | +$58.4M |
|
3
Galapagos
GLPG
$2.07B
| $198M | 6.2% | 3,195,624 +971,221 | +44% | +$60.2M |
|
4
AnaptysBio
ANAB
$569M
| $186M | 5.82% | 7,521,024 | – | – |
|
|
5
Sarepta Therapeutics
SRPT
$1.78B
| $162M | 5.06% | +2,069,634 | New | +$162M |
|
|
MORF
6
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $159M | 4.96% | 3,951,566 | – | – |
|
|
7
Acadia Pharmaceuticals
ACAD
$4.38B
| $145M | 4.54% | 5,991,479 +2,930,886 | +96% | +$71M |
|
8
Xencor
XNCR
$580M
| $133M | 4.15% | 4,968,756 +62,650 | +1% | +$1.67M |
|
9
Kura Oncology
KURA
$686M
| $107M | 3.34% | 6,638,371 +2,913,934 | +78% | +$46.9M |
|
|
10
Arcus Biosciences
RCUS
$1.13B
| $103M | 3.22% | 3,265,101 -2,258,257 | -41% | -$71.3M |
|
|
11
Arvinas
ARVN
$568M
| $101M | 3.17% | 1,503,929 +1,373,629 | +1,054% | +$92.4M |
|
|
12
Zai Lab
ZLAB
$3.68B
| $97.8M | 3.06% | +2,223,212 | New | +$97.8M |
|
13
Alector
ALEC
$238M
| $81.8M | 2.56% | 5,738,448 +743,478 | +15% | +$10.6M |
|
14
Nuvation Bio
NUVB
$1.02B
| $73.1M | 2.29% | 13,896,543 | – | – |
|
15
Relay Therapeutics
RLAY
$619M
| $68.6M | 2.15% | 2,291,441 +512,357 | +29% | +$15.3M |
|
|
RETA
16
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $64.7M | 2.02% | +1,975,611 | New | +$64.7M |
|
|
TSVT
17
DELISTED
2seventy bio
TSVT
| $59.6M | 1.87% | 3,495,943 +1,578,880 | +82% | +$26.9M |
|
|
CERE
18
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $57.6M | 1.8% | +1,646,260 | New | +$57.6M |
|
19
Avidity Biosciences
RNA
$5.99B
| $51M | 1.59% | 2,759,505 | – | – |
|
20
Atea Pharmaceuticals
AVIR
$267M
| $45.8M | 1.43% | 6,340,639 +964,505 | +18% | +$6.96M |
|
|
MRTX
21
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $41.2M | 1.29% | +500,622 | New | +$41.2M |
|
22
argenx
ARGX
$43.6B
| $39.4M | 1.23% | +125,000 | New | +$39.4M |
|
23
Design Therapeutics
DSGN
$315M
| $38.3M | 1.2% | 2,371,445 +218,448 | +10% | +$3.53M |
|
24
Revolution Medicines
RVMD
$7.1B
| $32.5M | 1.02% | +1,274,097 | New | +$32.5M |
|
25
Vaxcyte
PCVX
$4B
| $31.5M | 0.99% | 1,304,741 +1,283,941 | +6,173% | +$31M |
|